Literature DB >> 8946777

Haematological variables in prostatic carcinoma patients.

R W Geenen1, K P Delaere, J W van Wersch.   

Abstract

Routine laboratory tests of the red, white and platelet blood cell systems were performed in 49 patients with benign prostatic hyperplasia (BPH), in 24 hormonally treated patients with metastatic prostatic carcinoma, in 17 patients with untreated prostatic carcinoma without metastases and in 14 patients with untreated metastatic prostatic carcinoma. Significantly lower erythrocyte counts, haemoglobin levels and haematocrit values were found in the hormonally treated cancer group compared to all three other groups. The untreated metastatic cancer group had significantly lower haemoglobin levels and haematocrit values compared to the untreated non-metastatic cancer group. These results indicate that patients with metastases were developing anaemia and that this development was not influenced by palliative hormonal therapy. The results of this study showed that abnormal platelet counts in patients with prostatic carcinoma were rare and that the white blood cell system did not seem to be affected in patients with prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946777

Source DB:  PubMed          Journal:  Acta Urol Belg        ISSN: 0001-7183


  3 in total

1.  Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

Authors:  Elba C Etchebehere; Denái R Milton; John C Araujo; Nancy M Swanston; Homer A Macapinlac; Eric M Rohren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-29       Impact factor: 9.236

2.  Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.

Authors:  Carsten Nieder; Ellinor Haukland; Adam Pawinski; Astrid Dalhaug
Journal:  BMC Cancer       Date:  2010-06-13       Impact factor: 4.430

Review 3.  A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?

Authors:  E Hormbrey; P Gillespie; K Turner; C Han; A Roberts; D McGrouther; A L Harris
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.